Page 138 - 《中国药房》2021年8期

pathophysiology[M]. Boston：Academic Press，2017：145- [38] BUTS J，DEKEYSER N，STILMANT C，et al. Saccharo-
164. myces boulardii produces in rat small intestine a novel
[24] MOHR K I. History of antibiotics research[J]. Curr Top protein phosphatase that inhibits Escherichia coli endoto-
Microbiol Immunol，2016，398：237-272. xin by dephosphorylation[J]. Pediatr Res，2006，60（1）：
[25] BUCKNER M，CIUSA M L，PIDDOCK L. Strategies to 24-29.
combat antimicrobial resistance：anti-plasmid and plasmid [39] JUSTINO P，FRANCO A X，PONTIER-BRES R，et al.
curing[J]. FEMS Microbiol Rev，2018，42（6）：781-804. Modulation of 5-fluorouracil activation of Toll-like/
[26] KAŹMIERCZAK-SIEDLECKA K，RUSZKOWSKI J， MyD88/NF-κ B/MAPK pathway by Saccharomyces bou-
FIC M，et al. Saccharomyces boulardii CNCM I-745：a lardii CNCM I-745 probiotic[J]. Cytokine，2020. DOI：
non-bacterial microorganism used as probiotic agent in 10.1016/j.cyto.2019.154791.
supporting treatment of selected diseases[J]. Curr Micro- [40] CHEN X，KOKKOTOU E G，MUSTAFA N，et al. Saccha-
biol，2020，77（9）：1987-1996. romyces boulardii inhibits ERK1/2 mitogen-activated pro-
[27] MORÉ M I，SWIDSINSKI A. Saccharomyces boulardii tein kinase activation both in vitro and in vivo and pro-
CNCM I-745 supports regeneration of the intestinal micro- tects against Clostridium difficile toxin A-induced enteri-
biota after diarrheic dysbiosis[J]. Clin Exp Gastroenterol， tis[J]. J Biol Chem，2006，281（34）：24449-24454.
2015，8：237-255. [41] CHANG C，WANG K，ZHOU S N，et al. Protective Effect
[28] 武庆斌，郑跃杰，黄永坤.儿童肠道菌群基础与临床[M]. of Saccharomyces boulardii on deoxynivalenol-induced in-
北京：科学出版社，2019：212-227. jury of porcine macrophage via attenuating p38 mapk sig-
[29] GRAFF S，CHAUMEIL J C，BOY P，et al. Formulations nal pathway[J]. Appl Biochem Biotechnol，2017，182（1）：
for protecting the probiotic Saccharomyces boulardii from 411-427.
degradation in acidic condition[J]. Biol Pharm Bull，2008， [42] MORÉ M I. Saccharomyces boulardii CNCM I-745：the
31（2）：266-272. medicinal yeast improves intestinal enzyme function[J].
[30] CORDONNIER C，THÉVENOT J，ETIENNE-MESMIN MMW Fortschr Med，2019，161（Suppl 4）：S20-S24.
L，et al. Dynamic in vitro models of the human gastroin- [43] RODRIGUES A C，CARA D C，FRETEZ S H，et al. Sac-
testinal tract as relevant tools to assess the survival of pro- charomyces boulardii stimulates sIgA production and the
biotic strains and their interactions with gut microbiota[J]. phagocytic system of gnotobioticmice[J]. J Appl Micro-
Microorganisms，2015，3（4）：725-745. biol，2000，89（3）：404-414.
[31] GHORBANI-CHOBOGHLO H，NIKAEIN D，KHOSRA- [44] WAN C M，YU H，LIU G，et al. A multicenter randomized
VI A R，et al. Effect of microencapsulation on Saccharo- controlled study of Saccharomyces boulardii in the pre-
myces cerevisiae var. boulardii viability in the gastrointes- vention of antibiotic-associated diarrhea in infants and
tinal tract and level of some blood biochemical factors in young children[J]. Zhonghua Er Ke Za Zhi，2017，55（5）：
wistar rats[J]. Iran J Microbiol，2019，11（2）：160-165. 349-354.
[32] BLEHAUT H，MASSOT J，ELMER G W，et al. Disposi- [45] SZAJEWSKA H，KOŁODZIEJ M. Systematic review
tion kinetics of Saccharomyces boulardii in man and with meta-analysis：Saccharomyces boulardii in the pre-
rat[J]. Biopharm Drug Dispos，1989，10（4）：353-364. vention of antibiotic-associated diarrhoea[J]. Aliment
[33] MORÉ M I，VANDENPLAS Y. Saccharomyces boulardii Pharmacol Ther，2015，42（7）：793-801.
CNCM I-745 improves intestinal enzyme function：a tro- [46] SHAN L S，HOU P，WANG Z J，et al. Prevention and
phic effects review[J/OL]. Clin Med Insights Gastroen- treatment of diarrhoea with Saccharomyces boulardii in
terol，2018[2020-12-21]. https：//www.ncbi.nlm.nih.gov/pmc/ children with acute lower respiratory tract infections[J].
articles/PMC5808955/.DOI：10.1177/1179552217752679. Benef Microbes，2013，4（4）：329-334.
[34] BERMUDEZ-BRITO M，PLAZA-DÍAZ J，MUÑOZ- [47] ROMANIO M R，CORAINE L A，MAIELO V P，et al.
QUEZADA S，et al. Probiotic mechanisms of action[J]. Saccharomyces cerevisiaefungemia in a pediatric patient
Ann Nutr Metab，2012，61（2）：160-174. after treatment with probiotics[J]. Revista Paulista de Pedi-
[35] BAJAJ B K，CLAES I，LEBEER S. Functional mecha- atria，2017，35（3）：361-364.
nisms of probiotics[J]. J Microbiol，Biotechnol Food Sci， [48] HWANG J B，KANG K J，KANG Y N，et al. Probiotic
2015，4（4）：321-327. gastrointestinal allergic reaction caused by Saccharomy-
[36] ENER C D，ATES K，METEHAN O，et al. Saccharomy- ces boulardii[J]. Ann Allergy Asthma Immunol，2009，103
cesboulardii CNCM I-745 in different clinical condi- （1）：87-88.
tions[J]. Expert Opin Biol Ther，2014，14（11）：1593-1609. [49] IVANOVSKA V，RADEMAKER C M，VAN DIJK L，et al.
[37] HAN Y，LOU J. Efficacy of Saccharomyces boulardii in Pediatric drug formulations：a review of challenges and
the prevention of diarrhea secondary to pneumonia in chil- progress[J]. Pediatrics，2014，134（2）：361-372.
dren：a randomized controlled multicenter clinical study[J]. （收稿日期：2020-11-17 修回日期：2021-02-04）
CJPP，2020，35（11）：866-871. （编辑：孙 冰）

·1024 · China Pharmacy 2021 Vol. 32 No. 8 中国药房 2021年第32卷第8期